Neulasta (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Neulasta, is a Granulocyte colony‑stimulating factor (G‑CSF) presented as a 6 mg injection (prefilled syringe) for subcutaneous use. It reduces the duration of chemotherapy‑induced neutropenia and assists in mobilizing peripheral blood stem cells for collection.

GNH USA supplies Neulasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neulasta (pegfilgrastim) is a granulocyte colony‑stimulating factor used to support patients undergoing myelosuppressive chemotherapy.

- Chemotherapy‑induced neutropenia: reduces the duration and severity of neutropenia in patients receiving myelosuppressive chemotherapy. - Peripheral blood stem cell mobilization: facilitates collection of stem cells for autologous transplantation. - Hematopoietic recovery after high‑dose chemotherapy: accelerates neutrophil recovery to lower infection risk.

Common Side Effects: - Bone pain: mild to moderate discomfort often reported after injection. - Injection site reactions: redness, swelling, or tenderness at the administration site. - Fatigue: transient feeling of tiredness. - Nausea: occasional upset stomach. - Headache: mild headache may occur.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis, angioedema, or rash requiring immediate medical attention. - Splenic rupture: rare but potentially life‑threatening abdominal emergency. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty. - Capillary leak syndrome: sudden drop in blood pressure and fluid accumulation. - Leukocytosis: excessively high white blood cell counts.

Neulasta should be used under close medical supervision with attention to patient‑specific factors.

- Dose adjustment: follow prescriber instructions based on chemotherapy regimen and patient characteristics. - Renal impairment: monitor patients with severe renal dysfunction, as clearance may be altered. - Bone pain management: assess and treat pain proactively, especially after the first dose. - Allergic reactions: discontinue immediately if signs of hypersensitivity appear. - Concomitant myeloid growth factors: avoid simultaneous use to prevent overlapping effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pegfilgrastim may interact with other agents that affect bone marrow or immune function.

Major Interactions (Avoid): - Concurrent use with other myeloid growth factors: may increase risk of bone marrow suppression. - Live vaccines: may reduce vaccine efficacy; avoid administration during treatment.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy: timing must be coordinated to avoid reduced chemotherapy efficacy. - Antibiotics that affect neutrophil function: monitor blood counts for additive effects. - Corticosteroids: may mask signs of infection; observe patients closely.